Management Team

Luis de Luzuriaga serves as the Chief Executive Officer and is a member of the Board of Directors of Biocare Medical Ltd. In this position, Mr. de Luzuriaga reports to the Board of Directors and is responsible for driving the organization to meet customer satisfaction and market growth objectives. A seasoned executive, Mr. de Luzuriaga has held senior leadership positions with Abbott, Bayer, and Leica Biosystem (A Danaher Company). Mr. de Luzuriaga is a dynamic, global leader who has successfully transformed businesses by focusing the organizations on strategy and execution. He can rally the team around his vision and rapidly drive cultural shifts while yielding quick results. Luis provides the confidence to the organization that they can, and will be, successful. Mr. de Luzuriaga is a graduate of Tufts University and served as an officer in the US Army. He is married with four children.

John Steel is a versatile and top-performing marketing professional with over 20 years of proven success in B2B clinical and biotechnology markets. Broad exposure to web development, brand development, product marketing, sales and complex research. Focus on B2B and serving customers involved in clinical diagnostics through commercialization of a combined product and service offering. John Steel has been integral in Biocare’s acquisition process by two private equity companies and aided in two acquisitions that Biocare Medical has made over his 17 years with the company. In his free time, John enjoys building and remodeling homes. He is also 2003 regional, national, and world yoyo champion and one of 15 national yoyo masters worldwide.

Dr. Nowak is recognized as a leader in the field of human genomics.  Her research contributed directly to the Human Genome Project, as well as to genomic based approaches to understanding heritable disorders and cancer. Dr. Nowak is the founder and Chief Scientific Officer of Empire Genomics. In 2015, Dr. Nowak was named executive director for the University at Buffalo (UB) New York State Center of Excellence in Bioinformatics and Life Sciences, and holds the rank of Professor of Biochemistry. Dr. Nowak was appointed to the Empire State Stem Cell Board in 2014.  She also serves as Principal Investigator, UB Center for Advanced Technology in BIG Data and Health Sciences, as of the July 1, 2017 redesignation.

Among her major achievements, Dr. Nowak has authored landmark papers describing the cloning of several heritable cancer disorders, including a form of Ataxia Telangiectasia (Nijmegen Breakage Syndrome). Her work on the Human Genome Project was published in the 2001 landmark genome issue of Nature describing the sequencing of the human genome. Dr. Nowak led and coordinated the three groups for the NCI extramural Cancer Chromosome Aberration Project. As part of this project, Dr. Nowak also developed BAC based array CGH (Comparative Genomic Hybridization), a microarray-based method for identifying numerical differences in DNA between tumor and normal cells and cells from individuals with genetic disorders, including autism and other developmental disorders. The results of this work were published in Nature Genetics.

Dr. Nowak’s efforts were instrumental in obtaining more than $70 million in funding for research and infrastructure and she has authored or co-authored 145 research articles in leading scientific journals.  She also has served on the editorial board of Cytogenetics and Genome Research as well as an Associate Editor of Physiological Genomics. Read her full bio here.